Paul Hudson, Sanofi's chief executive officer, seeks to convince investors that the company can successfully develop a new generation of medicines independently.
Investor confidence was affected following the company's stock decline in October, when Hudson eliminated a margin target for 2025 and announced increased spending on research and development.
Although he has acknowledged the need for better communication, Sanofi's problems also include investor concerns about its dependence on Dupixent for asthma and eczema.
Dupixent's projected sales exceed 20 billion euros by 2030, representing one-third of expected revenues for the decade.
Dupixent's exclusivity rights will expire in the early 2030s. Despite investor doubts, Sanofi insists it has 12 possible blockbuster successes in development, with collective sales potential of between 33 billion and 60 billion euros. These include amlitelimab for eczema treatment and frexalimab for multiple sclerosis.
Although the company spent 6.7 billion euros on research and development last year, it plans to invest an additional 700 million euros next year.
Sanofi argues that these efforts are fundamental to its "play to win" strategy, but investors will expect to see concrete results from these research and development commitments.
Sanofi's current valuation in terms of forward price-to-earnings multiple is 11 times, compared to 12.4 and 16.56 times for Roche and AstraZeneca, respectively.
With information from: Teknomers.
Receive all industry news in our weekly Newsletter Scientific Dialectics.